Description:

The radiopharmaceutical Meta-iodobenzylguanidine, labelled with iodine-123, is supplied in an isotonic, limpid, injectable solution. It is used to diagnose neuroblastomas and heart diseases.

Technical characteristics:

Chemical form: Meta-iodobenzylguanidine (MIBG) Solution: limpid, sterile, apyrogenic, injectable pH: 7 (seven) Radiochemistry purity: > 97% Radionuclidic purity: > 99% Calibration: for use on Wednesdays at 8h Distribution: ready for transportation as of 12h on Tuesdays Storage: 8°C

Application:

Due to a half-life of only 13.2 hours, iodine-123 (MIBG) allows the diagnosis of heart diseases and tumors. However, iodine-131 (MIBG), due to a longer half-live (eight days) is more suitable to the treatment of tumors with higher doses.

With the production of iodine-123 ultrapure, IEN follows a worldwide trend to make short half-life radioisotopes available for exams and therapy. Due to its half-life of only 13.2 hours, iodine-123 substitutes iodine-131 (8 days of half-life) with advantage, making the exams less aggressive to the patient.